Advances in Chronic Kidney Disease
Volume 16, Issue 4 , Pages 226-233 , July 2009

Kidney Transplantation: The Ideal Immunosuppression Regimen

  • Julie M. Yabu

      Affiliations

    • Department of Medicine, Division of Nephrology, Stanford University Medical Center, Palo Alto, CA
    • Corresponding Author InformationAddress correspondence to Julie M. Yabu, MD, Department of Medicine, Division of Nephrology, Stanford University Medical Center, 780 Welch Road, Room 106, Palo Alto, CA 94304.
    • ,
  • Flavio Vincenti

      Affiliations

    • Department of Medicine and Surgery, University of California, San Francisco, San Francisco, CA

References 

  1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605–612
  2. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378–383
  3. Danovitch GM. Immunosuppressive medications and protocols for kidney transplantation. In:  Danovitch GM editors. Handbook of Kidney Transplantation. ed 4. Philadelphia, PA: Lippincott Williams & Wilkins; 2005;p. 72–134
  4. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715–2729
  5. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998;338:161–165
  6. Nashan B, Moore R, Amlot P, et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 1997;350:1193–1198
  7. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant. 2002;2:48–56
  8. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation. N Engl J Med. 2006;355:67–77
  9. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplant. 2003;76:120–129
  10. 2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006. Rockville, MD, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD
  11. Nankivell BK, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation. 2004;78:557–565
  12. Mayer AD for the European Tacrolimus Multicenter Renal Study Group. Chronic rejection and graft half-life: Five-year follow-up of the European tacrolimus multicenter renal study. Transplant Proc. 2002;34:1491–1492
  13. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation. 2002;73:775–782
  14. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506–1514
  15. Guichard SW. Nutrition in the kidney transplant. In:  Danovitch GM editors. Handbook of Kidney Transplantation. ed 4. Philadelphia, PA: Lippincott Williams & Wilkins; 2005;p. 475–494
  16. Kaplan B, Schold JS, Meier-Kriesche H-U. Long-term graft survival with neoral and tacrolimus: A paired kidney analysis. J Am Soc Nephrol. 2003;14:2980–2984
  17. Andrassy J, Graeb C, Rentsch M. mTOR inhibition and its effect on cancer in transplantation. Transplantation. 2005;80:5171–5174
  18. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med. 2002;8:128–135
  19. Stallone G, Schena A, Infante B, et al. Sirolimus for kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317–1323
  20. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60:225–232
  21. Meier-Kriesche H-U, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation. 2003;75:1341–1346
  22. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the national transplantation pregnancy registry (NTPR): outcomes of pregnancy after transplantation. In:  Cecka JM,  Terasaki PI editor. Clinical Transplants. Los Angeles, CA: Terasaki Foundation Laboratory; 2004;p. 103–114
  23. Fuchs KM, Constan DR. Immunosuppressant therapy in pregnant organ transplant recipients. Semin Perinatol. 2007;31:363–371
  24. Sahadevan M, Kasiske BL. Long-term posttransplant management and complications. In:  Danovitch GM editors. Handbook of Kidney Transplantation. ed 4. Philadelphia, PA: Lippincott Williams & Wilkins; 2005;p. 234–278
  25. Sifontis NM, Coscia LA, Constantinescu S, et al. Pregnancy outcomes in solid organ recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82:1698–1702
  26. Zuber J, Anglicheau D, Elie C. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant. 2008;8:1471–1479
  27. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984;311:699–705
  28. Sibley RK, Rynasiewicz J, Ferguson RM, et al. Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone. Surgery. 1983;94:225–234
  29. Sommer BG, Innes JT, Whitehurst RM, et al. Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. Am J Surg. 1985;149:756–764
  30. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001;71:1282–1287
  31. Grinyo JM, Gil-Vernet S, Cruzado JM, et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: Results after 5 years. Transpl Int. 2003;16:820–827
  32. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002;74:1070–1076
  33. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–2575
  34. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001;72:777–786
  35. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int. 2005;18:22–28
  36. Baboolal K. A phase III, prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months n de novo renal allograft recipients. Transplantation. 2003;75:1404–1408
  37. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab, and corticosteroids in renal allograft recipients. The CAESAR Study. Am J Transplant. 2007;7:560–570
  38. Hazzan M, Labalette M, Copin MC, et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: Results from a prospective, randomized trial. J Am Soc Nephrol. 2005;16:2509–2516
  39. Pearson TC, Mulgaonkar S, Patel A, et al. Efficacy and safety of mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: Final results of the spare-the-nephron (STN) trial. [AST abstract 129] Am J Transplant. 2008;2:213
  40. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233–242
  41. Hricik DE, O'Toole MA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: A meta-analysis. J Am Soc Nephrol. 1993;4:1300–1305
  42. Kasiske BL, Chakkira HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol. 2000;11:1910–1917
  43. Vincenti F, Schena FP, Paraskevas S, et al. FREEDOM Study Group A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008;8:307–316
  44. Woodle ES, First MR, Pirsch J, et al. for the Astellas Cortiocosteroid Withdrawal Study Group A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564–577
  45. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant. 2008;8:1972–1981
  46. Yabu JM, Vincenti F. Novel immunosuppression: Small molecules and biologics. Semin Nephrol. 2007;27:479–486
  47. Starzl TE. Acquired immunologic tolerance: With particular reference to transplantation. Immunol Res. 2007;38:6–41
  48. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008;358:362–368
  49. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358:353–361

PII: S1548-5595(09)00081-0

doi: 10.1053/j.ackd.2009.04.003

Advances in Chronic Kidney Disease
Volume 16, Issue 4 , Pages 226-233 , July 2009

Article Tools